Literature DB >> 3838365

Elevated plasma 1,25-dihydroxyvitamin D concentrations in infants with hypercalcemia and an elfin facies.

M Garabédian, E Jacqz, H Guillozo, R Grimberg, M Guillot, M F Gagnadoux, M Broyer, G Lenoir, S Balsan.   

Abstract

We measured plasma concentrations of 1,25-dihydroxyvitamin D (1,25-(OH)2D) in the course of a 6-to-37-month survey of four children with hypercalcemia and an elfin facies (Williams syndrome). Levels of 1,25-(OH)2D were elevated (160 to 470 pg per milliliter) during the hypercalcemic phase of the disease, when the children were five to nine months old, and they decreased thereafter. Plasma 1,25 (OH)2D levels were higher than those found in three children (16 to 60 months old) with the elfin facies syndrome and no hypercalcemia (42 to 71 pg per milliliter) and eight children (1 to 36 months old) with hypercalcemia and no dysmorphy (12 to 140 pg per milliliter), including two children with vitamin D intoxication. Hypercalcemia in the three children with elfin facies was controlled by a low-calcium diet. Serum calcium levels fell to the normal range, and plasma 1,25-(OH)2D levels were normal for age (18 to 105 pg per milliliter) at 14 to 47 months of age, even after appropriate therapy had been discontinued. These observations suggest that hypercalcemia may be the consequence of abnormal synthesis or degradation of 1,25-(OH)2D in children with the elfin facies syndrome.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838365     DOI: 10.1056/NEJM198504113121503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  15 in total

Review 1.  Vitamin D and autism, what's new?

Authors:  John Jacob Cannell
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

2.  Bedside assessment of hypercalcaemia.

Authors:  F P Muldowney; R Freaney; M J McKenna
Journal:  Ir J Med Sci       Date:  1988-11       Impact factor: 1.568

Review 3.  Endocrine control and disturbances of calcium and phosphate metabolism in children.

Authors:  K Kruse
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

4.  Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness.

Authors:  Bruce W Hollis; Donna Johnson; Thomas C Hulsey; Myla Ebeling; Carol L Wagner
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

5.  Hypercalcemia in infants presenting with apnea.

Authors:  S W Kooh; A Binet
Journal:  CMAJ       Date:  1990-09-15       Impact factor: 8.262

6.  Symptomatic hypercalcemia in the first months of life: calcium-regulating hormones and treatment.

Authors:  P Ghirri; U Bottone; L Coccoli; M Bernardini; M Vuerich; A Cuttano; C Riparbelli; G Pellegrinetti; A Boldrini
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

Review 7.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

8.  Vitamin D metabolites in idiopathic infantile hypercalcaemia.

Authors:  N D Martin; G J Snodgrass; R D Cohen; C E Porteous; R D Coldwell; D J Trafford; H L Makin
Journal:  Arch Dis Child       Date:  1985-12       Impact factor: 3.791

9.  Distinct function of 2 chromatin remodeling complexes that share a common subunit, Williams syndrome transcription factor (WSTF).

Authors:  Kimihiro Yoshimura; Hirochika Kitagawa; Ryoji Fujiki; Masahiko Tanabe; Shinichiro Takezawa; Ichiro Takada; Ikuko Yamaoka; Masayoshi Yonezawa; Takeshi Kondo; Yoshiyuki Furutani; Hisato Yagi; Shin Yoshinaga; Takeyoshi Masuda; Toru Fukuda; Yoko Yamamoto; Kanae Ebihara; Dean Y Li; Rumiko Matsuoka; Jun K Takeuchi; Takahiro Matsumoto; Shigeaki Kato
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-26       Impact factor: 11.205

10.  Endocrine dysfunctions in children with Williams-Beuren syndrome.

Authors:  Yoon-Myung Kim; Ja Hyang Cho; Eungu Kang; Gu-Hwan Kim; Eul-Ju Seo; Beom Hee Lee; Jin-Ho Choi; Han-Wook Yoo
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.